In melanoma and other cancers, invasion, epithelial-to-mesenchymal transition, metastasis and cancer stem cell maintenance are regulated by transcription factors including the Snail family. Slug (Snail2) protein generally supports migration and apoptosis resistance. However, its role in melanoma is not completely understood. The present study investigated the transcriptional regulation of the SLUG gene in melanoma. It demonstrated that SLUG is under the control of the Hedgehog/GLI signaling pathway and is activated predominantly by the transcription factor GLI2. The SLUG gene promoter contains a high number of GLI-binding sites. Slug expression is activated by GLI factors in reporter assays and inhibited by GANT61 (GLI inhibitor) and cyclopamine (SMO inhibitor). SLUG mRNA levels are lowered by GANT61 as assessed by reverse transcription-quantitative PCR. Chromatin immunoprecipitation revealed abundant binding of factors GLI1-3 in the four subregions of the proximal SLUG promoter. Notably, melanoma-associated transcription factor (MITF) is an imperfect activator of the SLUG promoter in reporter assays, and downregulation of MITF had no effect on endogenous Slug protein levels. Immunohistochemical analysis confirmed the above findings and showed MITF-negative regions in metastatic melanoma that were positive for GLI2 and Slug. Taken together, the results demonstrated a previously unrecognized transcriptional activation mechanism of the SLUG gene, which may represent its main regulation of expression in melanoma cells.

3rd Department of Surgery 1st Faculty of Medicine Charles University and University Hospital Motol 15006 Prague Czech Republic

Department of Pathology and Molecular Medicine 2nd Faculty of Medicine Charles University and University Hospital Motol 15006 Prague Czech Republic

Department of Transcription and Cell Signaling Institute of Medical Biochemistry and Laboratory Diagnostics 1st Faculty of Medicine Charles University and General University Hospital Prague 12108 Prague Czech Republic

See more in PubMed

Teglund S, Toftgård R. Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochim Biophys Acta. 2010;1805:181–208. PubMed

Varjosalo M, Taipale J. Hedgehog: Functions and mechanisms. Genes Dev. 2008;22:2454–2472. doi: 10.1101/gad.1693608. PubMed DOI

Marini KD, Payne BJ, Watkins DN, Martelotto LG. Mechanisms of Hedgehog signalling in cancer. Growth Factors. 2011;29:221–234. doi: 10.3109/08977194.2011.610756. PubMed DOI

Jeng KS, Chang CF, Lin SS. Sonic Hedgehog signaling in organogenesis, tumors, and tumor microenvironments. Int J Mol Sci. 2020;21:758. doi: 10.3390/ijms21030758. PubMed DOI PMC

Lauth M, Bergström A, Shimokawa T, Tostar U, Jin Q, Fendrich V, Guerra C, Barbacid M, Toftgård R. DYRK1B-dependent autocrine-to-paracrine shift of Hedgehog signaling by mutant RAS. Nat Struct Mol Biol. 2010;17:718–725. doi: 10.1038/nsmb.1833. PubMed DOI

Stecca B, Mas C, Clement V, Zbinden M, Correa R, Piguet V, Beermann F, Ruiz IA, Altaba A. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc Natl Acad Sci USA. 2007;104:5895–5900. doi: 10.1073/pnas.0700776104. PubMed DOI PMC

Riobó NA, Lu K, Ai X, Haines GM, Emerson CP., Jr Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling. Proc Natl Acad Sci USA. 2006;103:4505–4510. doi: 10.1073/pnas.0504337103. PubMed DOI PMC

Mangelberger D, Kern D, Loipetzberger A, Eberl M, Aberger F. Cooperative Hedgehog-EGFR signaling. Front Biosci (Landmark Ed) 2012;17:90–99. doi: 10.2741/3917. PubMed DOI PMC

Faião-Flores F, Alves-Fernandes DK, Pennacchi PC, Sandri S, Vicente AL, Scapulatempo-Neto C, Vazquez VL, Reis RM, Chauhan J, Goding CR, et al. Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells. Oncogene. 2017;36:1849–1861. doi: 10.1038/onc.2016.348. PubMed DOI PMC

Santini R, Pietrobono S, Pandolfi S, Montagnani V, D'Amico M, Penachioni JY, Vinci MC, Borgognoni L, Stecca B. SOX2 regulates self-renewal and tumorigenicity of human melanoma-initiating cells. Oncogene. 2014;33:4697–4708. doi: 10.1038/onc.2014.71. PubMed DOI PMC

Pandolfi S, Montagnani V, Lapucci A, Stecca B. HEDGEHOG/GLI-E2F1 axis modulates iASPP expression and function and regulates melanoma cell growth. Cell Death Differ. 2015;22:2006–2019. doi: 10.1038/cdd.2015.56. PubMed DOI PMC

Nieto MA. The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol. 2002;3:155–166. doi: 10.1038/nrm757. PubMed DOI

Cohen ME, Yin M, Paznekas WA, Schertzer M, Wood S, Jabs EW. Human SLUG gene organization, expression, and chromosome map location on 8q. Genomics. 1998;51:468–471. doi: 10.1006/geno.1998.5367. PubMed DOI

Pérez-Mancera PA, González-Herrero I, Maclean K, Turner AM, Yip MY, Sánchez-Martín M, García JL, Robledo C, Flores T, Gutiérrez-Adán A, et al. SLUG (SNAI2) overexpression in embryonic development. Cytogenet Genome Res. 2006;114:24–29. doi: 10.1159/000091924. PubMed DOI

Wang Y, Shi J, Chai K, Ying X, Zhou BP. The role of snail in EMT and tumorigenesis. Curr Cancer Drug Targets. 2013;13:963–972. doi: 10.2174/15680096113136660102. PubMed DOI PMC

Bolós V, Peinado H, Pérez-Moreno MA, Fraga MF, Esteller M, Cano A. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: A comparison with Snail and E47 repressors. J Cell Sci. 2003;116:499–451. doi: 10.1242/jcs.00224. PubMed DOI

Wels C, Joshi S, Koefinger P, Bergler H, Schaider H. Transcriptional activation of ZEB1 by Slug leads to cooperative regulation of the epithelial-mesenchymal transition-like phenotype in melanoma. J Invest Dermatol. 2011;131:1877–1885. doi: 10.1038/jid.2011.142. PubMed DOI PMC

Casas E, Kim J, Bendesky A, Ohno-Machado L, Wolfe CJ, Yang J. Snail2 is an essential mediator of Twist1-induced epithelial mesenchymal transition and metastasis. Cancer Res. 2011;71:245–254. doi: 10.1158/0008-5472.CAN-10-2330. PubMed DOI PMC

Brabletz S, Schuhwerk H, Brabletz T, Stemmler MP. Dynamic EMT: A multi-tool for tumor progression. EMBO J. 2021;40:e108647. doi: 10.15252/embj.2021108647. PubMed DOI PMC

Pérez-Mancera PA, González-Herrero I, Pérez-Caro M, Gutiérrez-Cianca N, Flores T, Gutiérrez-Adán A, Pintado B, Sánchez-Martín M, Sánchez-García I. SLUG in cancer development. Oncogene. 2005;24:3073–3082. doi: 10.1038/sj.onc.1208505. PubMed DOI

Cobaleda C, Pérez-Caro M, Vicente-Dueñas C, Sánchez-García I. Function of the zinc-finger transcription factor SNAI2 in cancer and development. Annu Rev Genet. 2007;41:41–61. doi: 10.1146/annurev.genet.41.110306.130146. PubMed DOI

Barbato L, Bocchetti M, Di Biase A, Regad T. Cancer stem cells and targeting strategies. Cells. 2019;8:926. doi: 10.3390/cells8080926. PubMed DOI PMC

Fenouille N, Tichet M, Dufies M, Pottier A, Mogha A, Soo JK, Rocchi S, Mallavialle A, Galibert MD, Khammari A, et al. The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion. PLoS One. 2012;7:e40378. doi: 10.1371/journal.pone.0040378. PubMed DOI PMC

Guo Q, Ning F, Fang R, Wang HS, Zhang G, Quan MY, Cai SH, Du J. Endogenous Nodal promotes melanoma undergoing epithelial-mesenchymal transition via Snail and Slug in vitro and in vivo. Am J Cancer Res. 2015;5:2098–2112. PubMed PMC

Pearlman RL, Montes de Oca MK, Pal HC, Afaq F. Potential therapeutic targets of epithelial-mesenchymal transition in melanoma. Cancer Lett. 2017;391:125–140. doi: 10.1016/j.canlet.2017.01.029. PubMed DOI PMC

Arienti C, Tesei A, Carloni S, Ulivi P, Romeo A, Ghigi G, Menghi E, Sarnelli A, Parisi E, Silvestrini R, Zoli W. SLUG silencing increases radiosensitivity of melanoma cells in vitro. Cell Oncol (Dordr) 2013;36:131–139. doi: 10.1007/s13402-012-0120-6. PubMed DOI

Gupta PB, Kuperwasser C, Brunet JP, Ramaswamy S, Kuo WL, Gray JW, Naber SP, Weinberg RA. The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet. 2005;37:1047–1054. doi: 10.1038/ng1634. PubMed DOI PMC

Shirley SH, Greene VR, Duncan LM, Torres Cabala CA, Grimm EA, Kusewitt DF. Slug expression during melanoma progression. Am J Pathol. 2012;180:2479–2489. doi: 10.1016/j.ajpath.2012.02.014. PubMed DOI PMC

Caramel J, Papadogeorgakis E, Hill L, Browne GJ, Richard G, Wierinckx A, Saldanha G, Osborne J, Hutchinson P, Tse G, et al. A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell. 2013;24:466–480. doi: 10.1016/j.ccr.2013.08.018. PubMed DOI

Gunarta IK, Li R, Nakazato R, Suzuki R, Boldbaatar J, Suzuki T, Yoshioka K. Critical role of glioma-associated oncogene homolog 1 in maintaining invasive and mesenchymal-like properties of melanoma cells. Cancer Sci. 2017;108:1602–1611. doi: 10.1111/cas.13294. PubMed DOI PMC

Vlčková K, Ondrušová L, Vachtenheim J, Réda J, Dundr P, Zadinová M, Žáková P, Poučková P. Survivin, a novel target of the Hedgehog/GLI signaling pathway in human tumor cells. Cell Death Dis. 2016;7:e2048. doi: 10.1038/cddis.2015.389. PubMed DOI PMC

Vlčková K, Vachtenheim J, Réda J, Horák P, Ondrušová L. Inducibly decreased MITF levels do not affect proliferation and phenotype switching but reduce differentiation of melanoma cells. J Cell Mol Med. 2018;22:2240–2251. doi: 10.1111/jcmm.13506. PubMed DOI PMC

Miller AJ, Du J, Rowan S, Hershey CL, Widlund HR, Fisher DE. Transcriptional regulation of the melanoma prognostic marker melastatin (TRPM1) by MITF in melanocytes and melanoma. Cancer Res. 2004;64:509–516. doi: 10.1158/0008-5472.CAN-03-2440. PubMed DOI

Sánchez-Martín M, Rodríguez-García A, Pérez-Losada J, Sagrera A, Read AP, Sánchez-García I. SLUG (SNAI2) deletions in patients with Waardenburg disease. Hum Mol Genet. 2002;11:3231–3236. doi: 10.1093/hmg/11.25.3231. PubMed DOI

Sánchez-Martín M, Pérez-Losada J, Rodríguez-García A, González-Sánchez B, Korf BR, Kuster W, Moss C, Spritz RA, Sánchez-García I. Deletion of the SLUG (SNAI2) gene results in human piebaldism. Am J Med Genet A. 2003;122A:125–132. doi: 10.1002/ajmg.a.20345. PubMed DOI

Goodall J, Carreira S, Denat L, Kobi D, Davidson I, Nuciforo P, Sturm RA, Larue L, Goding CR. Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells. Cancer Res. 2008;68:7788–7794. doi: 10.1158/0008-5472.CAN-08-1053. PubMed DOI

Roessler E, Ermilov AN, Grange DK, Wang A, Grachtchouk M, Dlugosz AA, Muenke M. A previously unidentified amino-terminal domain regulates transcriptional activity of wild-type and disease-associated human GLI2. Hum Mol Genet. 2005;14:2181–2188. doi: 10.1093/hmg/ddi222. PubMed DOI

Kumasaka M, Sato S, Yajima I, Goding CR, Yamamoto H. Regulation of melanoblast and retinal pigment epithelium development by Xenopus laevis Mitf. Dev Dyn. 2005;234:523–534. doi: 10.1002/dvdy.20505. PubMed DOI

Vachtenheim J, Drdová B. A dominant negative mutant of microphthalmia transcription factor (MITF) lacking two transactivation domains suppresses transcription mediated by wild type MITF and a hyperactive MITF derivative. Pigment Cell Res. 2004;17:43–50. doi: 10.1046/j.1600-0749.2003.00108.x. PubMed DOI

Dynek JN, Chan SM, Liu J, Zha J, Fairbrother WJ, Vucic D. Microphthalmia-associated transcription factor is a critical transcriptional regulator of melanoma inhibitor of apoptosis in melanomas. Cancer Res. 2008;68:3124–3132. doi: 10.1158/0008-5472.CAN-07-6622. PubMed DOI

Ikram MS, Neill GW, Regl G, Eichberger T, Frischauf AM, Aberger F, Quinn A, Philpott M. GLI2 is expressed in normal human epidermis and BCC and induces GLI1 expression by binding to its promoter. J Invest Dermatol. 2004;122:1503–1509. doi: 10.1111/j.0022-202X.2004.22612.x. PubMed DOI

Parent AE, Choi C, Caudy K, Gridley T, Kusewitt DF. The developmental transcription factor slug is widely expressed in tissues of adult mice. J Histochem Cytochem. 2004;52:959–965. doi: 10.1369/jhc.4A6277.2004. PubMed DOI

Müller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, Kong X, Possik PA, Cornelissen-Steijger PD, Geukes Foppen MH, et al. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun. 2014;5:5712. doi: 10.1038/ncomms6712. PubMed DOI PMC

Tanno B, Sesti F, Cesi V, Bossi G, Ferrari-Amorotti G, Bussolari R, Tirindelli D, Calabretta B, Raschellà G. Expression of Slug is regulated by c-Myb and is required for invasion and bone marrow homing of cancer cells of different origin. J Biol Chem. 2010;285:29434–29445. doi: 10.1074/jbc.M109.089045. PubMed DOI PMC

Miao Y, Zhang W, Liu S, Leng X, Hu C, Sun H. HOXC10 promotes growth and migration of melanoma by regulating Slug to activate the YAP/TAZ signaling pathway. Discov Oncol. 2021;12:12. doi: 10.1007/s12672-021-00408-7. PubMed DOI PMC

Das S, Harris LG, Metge BJ, Liu S, Riker AI, Samant RS, Shevde LA. The hedgehog pathway transcription factor GLI1 promotes malignant behavior of cancer cells by up-regulating osteopontin. J Biol Chem. 2009;284:22888–22897. doi: 10.1074/jbc.M109.021949. PubMed DOI PMC

Zhang ZR, Yang N. MiR-33a-5p inhibits the growth and metastasis of melanoma cells by targeting SNAI2. Neoplasma. 2020;67:813–824. doi: 10.4149/neo_2020_190823N811. PubMed DOI

Alexaki VI, Javelaud D, Van Kempen LC, Mohammad KS, Dennler S, Luciani F, Hoek KS, Juàrez P, Goydos JS, Fournier PJ, et al. GLI2-mediated melanoma invasion and metastasis. J Natl Cancer Inst. 2010;102:1148–1159. doi: 10.1093/jnci/djq257. PubMed DOI PMC

Liu X, Hu Y, Yu B, Peng K, Gan X. CRKL is a critical target of Hh-GLI2 pathway in lung adenocarcinoma. J Cell Mol Med. 2021;25:6280–6288. doi: 10.1111/jcmm.16592. PubMed DOI PMC

Kim YH, Kwei KA, Girard L, Salari K, Kao J, Pacyna-Gengelbach M, Wang P, Hernandez-Boussard T, Gazdar AF, Petersen I, et al. Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer. Oncogene. 2010;29:1421–1430. doi: 10.1038/onc.2009.437. PubMed DOI PMC

Weiss JM, Hunter MV, Cruz NM, Baggiolini A, Tagore M, Ma Y, Misale S, Marasco M, Simon-Vermot T, Campbell NR, et al. Anatomic position determines oncogenic specificity in melanoma. Nature. 2022;604:354–361. doi: 10.1038/s41586-022-04584-6. PubMed DOI PMC

Jiang L, Huang J, Hu Y, Lu P, Luo Q, Wang L. Gli promotes tumor progression through regulating epithelial-mesenchymal transition in non-small-cell lung cancer. J Cardiothorac Surg. 2020;15:18. doi: 10.1186/s13019-020-1049-x. PubMed DOI PMC

Chun HW, Hong R. Significance of the hedgehog pathway-associated proteins Gli-1 and Gli-2 and the epithelial-mesenchymal transition-associated proteins Twist and E-cadherin in hepatocellular carcinoma. Oncol Lett. 2016;3:1753–1762. doi: 10.3892/ol.2016.4884. PubMed DOI PMC

Wang L, Jin JQ, Zhou Y, Tian Z, Jablons DM, He B. Gli is activated and promotes epithelial-mesenchymal transition in human esophageal adenocarcinoma. Oncotarget. 2017;9:853–865. doi: 10.18632/oncotarget.22856. PubMed DOI PMC

Kim JE, Leung E, Baguley BC, Finlay GJ. Heterogeneity of expression of epithelial-mesenchymal transition markers in melanocytes and melanoma cell lines. Front Oncol. 2013;4:97. PubMed PMC

Davies MA, Kopetz S. Overcoming resistance to MAPK pathway inhibitors. J Natl Cancer Inst. 2013;105:9–10. doi: 10.1093/jnci/djs507. PubMed DOI

Vachtenheim J, Ondrušová L. Many distinct ways lead to drug resistance in BRAF- and NRAS-mutated melanomas. Life (Basel) 2021;11:424. PubMed PMC

Vlčková K, Réda J, Ondrušová L, Krayem M, Ghanem G, Vachtenheim J. GLI inhibitor GANT61 kills melanoma cells and acts in synergy with obatoclax. Int J Oncol. 2016;49:953–960. doi: 10.3892/ijo.2016.3596. PubMed DOI